SUBSCRIBE
SUBSCRIBE

Forty Seven Inc.

NEWS
Forty Seven Inc. was acquired by Gilead in 2020.
Biotech Bay
Forty Seven Bags $75M, Bringing in a Total of $150M in Venture Capital
The round was led by new investors as well as existing investors.
October 17, 2017
 · 
2 min read
 · 
Mark Terry
Ex-Novartis AG Exec to Take the Reins at Bay Area's Forty Seven on May 1
Business
Ex-Novartis AG Exec to Take the Reins at Bay Area’s Forty Seven on May 1
March 21, 2017
 · 
2 min read
Business
The Next Generation: Top 20 Life Science Startups to Watch in 2017
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
January 3, 2017
 · 
11 min read
 · 
Mark Terry
Ex-Novartis AG Exec to Take the Reins at Bay Area's Forty Seven on May 1
Business
What You Need to Know About Forty Seven
January 3, 2017
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Forty Seven Launches with Half of $75 Million Series A Backed by Google and 100+ Patents
February 24, 2016
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS
Drug Development
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
December 9, 2019
 · 
7 min read
Biotech Bay
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
December 9, 2019
 · 
10 min read
Business
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
November 12, 2019
 · 
8 min read
Business
Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 12, 2019
 · 
12 min read
Drug Development
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual MeetingForty Seven to Host Investor Event and Webcast on December 9, 2019
November 6, 2019
 · 
5 min read
Business
Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 5, 2019
 · 
1 min read
Business
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
July 11, 2019
 · 
6 min read
Drug Development
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
June 18, 2019
 · 
12 min read
Business
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
May 10, 2019
 · 
7 min read
Drug Development
Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphoma
June 3, 2018
 · 
8 min read
Load More